![](https://investorshub.advfn.com/uicon/81806.png?cb=1635633872)
Wednesday, June 27, 2007 9:05:06 PM
Renovis Inc (RNVS)
Current Price: $4.18
Speculative Rating: 2
RNVS engages in the discovery and development of drugs for neurological diseases and disorders.
RNVS has had a research pact with Pfizer since 2005 and it was just extended until June 30th of 2008.
RNVS generated $10.1MM in revenues in 2006 from the Pfizer pact.
RNVS crashed at the end of October after their NXY-059 drugged failed.
However, RNVS has many other promising drugs under development and the stock is beginning to bounce back big.
RNVS's VR1 antagonist program with Pfizer is poised to enter clinical development this year and their P2X7 and P2X3 antagonist programs are on track to start clinical studies next year for inflammation and pain indications.
Found this on Lebed site.
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM